Keyphrases
Therapeutic Response
100%
MEK Inhibitor (MEKi)
100%
BRAF V600E
100%
BRAF Inhibitor (BRAFi)
100%
BRAF mutant
100%
Apoptotic Response
100%
Achilles Heel
100%
TERT Promoter mutation
100%
Tumor
55%
Apoptosis
33%
Cancer Cells
33%
Dabrafenib
22%
Trametinib
22%
Apoptosis Inhibition
22%
TERT Expression
22%
In Cancer
11%
Drug Resistance
11%
Human Cancer
11%
Tumor Recurrence
11%
Melanoma Cells
11%
Cancer Cell Models
11%
Cell Apoptosis
11%
Anticancer Activity
11%
Mitogen-activated Protein Kinase
11%
Induced Cell Death
11%
Thyroid Cancer
11%
Colon Cancer Cells
11%
Apoptotic Effect
11%
Patient Resistance
11%
Therapeutic Targeting
11%
Target Prediction
11%
Response Prediction
11%
Drug Withdrawal
11%
Duet
11%
Combination Use
11%
Biochemistry, Genetics and Molecular Biology
Promoter Region
100%
MEK Inhibitor
100%
Cancer Cell
66%
Trametinib
33%
Dabrafenib
33%
Genetics
16%
Drug Resistance
16%
Cell Death
16%
Colon
16%
Anticancer
16%
Mitogen-Activated Protein Kinase
16%
Drug Withdrawal
16%
Immunology and Microbiology
Promoter Region
100%
Cancer Cell
66%
Trametinib
33%
Drug Resistance
16%
Cell Death
16%
Colon
16%
Drug Withdrawal
16%